Business Context and Reporting Period
This Form 8-K reports on events occurring on August 27, 2024, specifically the 2024 Annual Meeting of Stockholders for Calcimedica, Inc. (Nasdaq: CALC). The company is incorporated in Delaware and operates as an emerging growth company.
Key Financial Metrics
This filing is a current report regarding corporate governance and equity plan amendments. It does not provide financial performance data such as revenue, profit, cash flow, margins, debt, or liquidity metrics. Investors should refer to the company's most recent 10-Q or 10-K for financial statements.
Material Changes and Voting Results
As of the record date (June 28, 2024), 10,750,156 shares were outstanding. Stockholders approved the following proposals:
- Proposal 1 (Election of Directors): Elected Eric Bjerkholt and Fred Middleton as Class I directors for a three-year term.
- Proposal 2 (Auditor Ratification): Ratified the appointment of Moss Adams LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2024.
- Proposal 3 (Equity Plan Amendment): Approved an amendment to the 2023 Equity Incentive Plan to increase the number of authorized shares by 1,500,000.
Voting Summary Table
| Proposal | Votes For | Votes Against/Withheld | Abstentions | Broker Non-Votes |
|---|---|---|---|---|
| Election of Eric Bjerkholt | 7,762,285 | 164,927 (Withheld) | N/A | 1,315,120 |
| Election of Fred Middleton | 5,630,077 | 2,297,135 (Withheld) | N/A | 1,315,120 |
| Ratification of Auditor | 9,075,082 | 167,110 | 140 | 0 |
| Equity Plan Amendment | 7,253,016 | 604,453 | 69,743 | 1,315,120 |
Guidance, Outlook, and Risks
This filing contains no management commentary regarding financial guidance, future outlook, or specific risk factors. The primary focus is the administrative approval of the equity plan amendment and the election of directors.
Investor Verification Checklist
- Verify the impact of the 1,500,000 share increase in the 2023 Equity Incentive Plan on potential future dilution.
- Review the full text of the 2023 Amended Plan (Exhibit 10.1) for specific terms regarding vesting and eligibility.
- Confirm the tenure of the newly elected directors (Eric Bjerkholt and Fred Middleton) through the 2027 annual meeting.
- Check the company's latest 10-Q or 10-K for financial health metrics, as this 8-K does not contain them.